tradingkey.logo

Urogen Pharma Says Zusduri Expected To Be Available In U.S. By July 1

ReutersJun 12, 2025 5:30 PM

- Urogen Pharma Ltd UR8.F:

  • U.S. FDA APPROVES UROGEN’S ZUSDURI™ (MITOMYCIN) FOR INTRAVESICAL SOLUTION AS THE FIRST AND ONLY MEDICATION FOR RECURRENT LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER (LG-IR-NMIBC)

  • UROGEN PHARMA LTD - ZUSDURI EXPECTED TO BE AVAILABLE IN U.S. BY JULY 1, 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI